These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26412161)

  • 1. Human ATP-Binding Cassette Transporter ABCB1 Confers Resistance to Volasertib (BI 6727), a Selective Inhibitor of Polo-like Kinase 1.
    Wu CP; Hsieh CH; Hsiao SH; Luo SY; Su CY; Li YQ; Huang YH; Huang CW; Hsu SC
    Mol Pharm; 2015 Nov; 12(11):3885-95. PubMed ID: 26412161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1.
    Wu CP; Hsiao SH; Luo SY; Tuo WC; Su CY; Li YQ; Huang YH; Hsieh CH
    Mol Pharm; 2014 Oct; 11(10):3727-36. PubMed ID: 25192198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
    Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
    Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
    Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
    Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.
    Chen JL; Chen JP; Huang YS; Tsai YC; Tsai MH; Jaw FS; Cheng JC; Kuo SH; Shieh MJ
    Strahlenther Onkol; 2016 Apr; 192(4):260-8. PubMed ID: 26952039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
    Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
    Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.
    Saatci Ö; Borgoni S; Akbulut Ö; Durmuş S; Raza U; Eyüpoğlu E; Alkan C; Akyol A; Kütük Ö; Wiemann S; Şahin Ö
    Oncogene; 2018 Apr; 37(17):2251-2269. PubMed ID: 29391599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.
    Van den Bossche J; Lardon F; Deschoolmeester V; De Pauw I; Vermorken JB; Specenier P; Pauwels P; Peeters M; Wouters A
    Med Res Rev; 2016 Jul; 36(4):749-86. PubMed ID: 27140825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
    Steegmaier M; Hoffmann M; Baum A; Lénárt P; Petronczki M; Krssák M; Gürtler U; Garin-Chesa P; Lieb S; Quant J; Grauert M; Adolf GR; Kraut N; Peters JM; Rettig WJ
    Curr Biol; 2007 Feb; 17(4):316-22. PubMed ID: 17291758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
    Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
    Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.
    Rudolph D; Impagnatiello MA; Blaukopf C; Sommer C; Gerlich DW; Roth M; Tontsch-Grunt U; Wernitznig A; Savarese F; Hofmann MH; Albrecht C; Geiselmann L; Reschke M; Garin-Chesa P; Zuber J; Moll J; Adolf GR; Kraut N
    J Pharmacol Exp Ther; 2015 Mar; 352(3):579-89. PubMed ID: 25576074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
    Sero V; Tavanti E; Vella S; Hattinger CM; Fanelli M; Michelacci F; Versteeg R; Valsasina B; Gudeman B; Picci P; Serra M
    Invest New Drugs; 2014 Dec; 32(6):1167-80. PubMed ID: 25193492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer.
    Ellis PM; Leighl NB; Hirsh V; Reaume MN; Blais N; Wierzbicki R; Sadrolhefazi B; Gu Y; Liu D; Pilz K; Chu Q
    Clin Lung Cancer; 2015 Nov; 16(6):457-65. PubMed ID: 26100229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.
    Lin SF; Lin JD; Yeh CN; Huang YT; Chou TC; Wong RJ
    Endocr Relat Cancer; 2019 Aug; 26(8):727-738. PubMed ID: 31189135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
    Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
    Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
    Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.
    Gorlick R; Kolb EA; Keir ST; Maris JM; Reynolds CP; Kang MH; Carol H; Lock R; Billups CA; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Jan; 61(1):158-64. PubMed ID: 23956067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.